Systematic evaluation of the clinical efficacy and intervention research of Qihuang Granules for dry AMD based on the theory of syndrome-disease combination

INTERVENTION: Trial Group:Qi Huang Granules (10g per bag, composed of Lycium barbarum, Cornus officinalis, Leonurus heterophyllus, Salvia miltiorrhiza, Platycodon grandiflorum, Bupleurum chinense, etc.), 1 bag three times daily, dissolved in warm water, continuous treatment for 3 months;Control Group:Lutein Tablets (10mg lutein per tablet), 1 tablet once daily orally, continuous treatment for 3 months; CONDITION: Dry age‐related macular degeneration PRIMARY OUTCOME: Retinal vascular flow density;Hemorheological parameters;NEI VFQ‐25;Best‐corrected visual acuity;Serum levels of the inflammatory cytokines IL?1ß, IL?18, and NLRP3;Multi‐spatial frequency contrast sensitivity function;Choroidal blood flow density and thickness;Amsler grid;Drusen volume; INCLUSION CRITERIA: 1. Age: 50–79 years, regardless of gender; 2. Meet the diagnostic criteria of dry AMD; 3. Meet the TCM syndrome criteria of liver‐kidney yin deficiency and phlegm‐stasis interminglement for dry AMD. 4. Patients without prior anti‐VEGF, laser or surgical treatment; 5. Patients with good compliance who can cooperate with ophthalmic examinations, complete standardized treatment, voluntarily provide clinical data, and provide signed informed consent.